Mylan CEO Defends EpiPen Price Hike

/

EipPenFighting critics who call the price hike "greedy" and "outrageous," Mylan CEO Heather Bresch makes no excuses for running a for-profit company. Yet the cost of an EpiPen has increased from about $165 in 2011 to more than $600 today. 

In a CNBC interview, Bresch stressed that "everybody who needs an EpiPen, has an EpiPen." She focused the costs involved in making the product widely available.

Trying to deflect blame, Bresch said, "This is a healthcare issue. . . . The system incentivizes higher prices." Pharmacy, retailers, and wholesalers are all taking a cut and are raising their prices. 

Discussion Starters:

  • Twice, Bresch said, "As a mother..." How effective is this strategy as part of her argument?
  • How well does Bresch convey her points? Which arguments do you find most and least convincing?
  • CNBC's chart is effective because it shows the dramatic increase over time. What's your view of the caption about skiing?